Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raloxifene Pharmacogenomics in Breast Cancer LCIS
NCT06062810Phase 3Active, not recruiting
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of raloxifene in breast cancer (2 arms). Primary endpoints: Raloxifene oncology drug target ER SNP Genotypes which are effectiveness associated at 12 weeks and Raloxifene oncology drug target UGT SNP Genotypes which are risk associated at 12 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
raloxifene
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06062810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062810.